Perfromance Wealth Partners LLC Buys 248 Shares of Edwards Lifesciences Co. (NYSE:EW)

Perfromance Wealth Partners LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.8% in the third quarter, HoldingsChannel.com reports. The fund owned 4,512 shares of the medical research company’s stock after acquiring an additional 248 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in Edwards Lifesciences were worth $298,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock worth $5,061,277,000 after buying an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after buying an additional 393,109 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after buying an additional 2,390,137 shares in the last quarter. Finally, Champlain Investment Partners LLC raised its holdings in shares of Edwards Lifesciences by 3.1% during the 1st quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after buying an additional 88,205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,250 shares of company stock valued at $751,688. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.2 %

NYSE EW opened at $68.13 on Friday. The business has a 50 day simple moving average of $67.13 and a 200 day simple moving average of $80.08. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a market capitalization of $41.06 billion, a P/E ratio of 29.37, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Research analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Evercore ISI dropped their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Citigroup dropped their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Truist Financial dropped their target price on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Finally, TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Seventeen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $75.77.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.